Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Fehse

Showing results (171-180 of 207) with videos related to

Pageof 21
Sort By:
Med (New York, N.Y.)|March 30, 2024
CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosisFelix Fischbach, Johanna Richter, Lena Kristina Pfeffer, et al.
Experimental Hematology|June 3, 2009
Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myelomaNicolaus Kröger, Anita Badbaran, Michael Lioznov, et al.
Hepatology (Baltimore, Md.)|April 9, 2014
Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolismNicola Oehler, Tassilo Volz, Oliver D Bhadra, et al.
Molecular Cancer Therapeutics|March 3, 2019
Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR AntibodiesJoseph Tintelnot, Natalie Baum, Christoph Schultheiß, et al.
Haematologica|August 11, 2022
Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapySusanna Carolina Berger, Boris Fehse, Nuray Akyüz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 20, 2012
Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myelomaNicolaus Kröger, Anita Badbaran, Tatjana Zabelina, et al.
Journal of the American Society of Nephrology : JASN|February 4, 2017
IL-33-Mediated Expansion of Type 2 Innate Lymphoid Cells Protects from Progressive GlomerulosclerosisJan-Hendrik Riedel, Martina Becker, Kerstin Kopp, et al.
Blood|February 17, 2005
Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesisUte Modlich, Olga S Kustikova, Manfred Schmidt, et al.
Oncotarget|June 11, 2015
Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancerFriederike Braig, Manuela März, Aneta Schieferdecker, et al.
The Journal of Clinical Investigation|July 1, 2020
Glioma escape signature and clonal development under immune pressureCecile L Maire, Malte Mohme, Michael Bockmayr, et al.
Pageof 21

Showing results (171-180 of 207) with videos related to

Sort By:
Pageof 21
Med (New York, N.Y.)|March 30, 2024
CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosisFelix Fischbach, Johanna Richter, Lena Kristina Pfeffer, et al.
Experimental Hematology|June 3, 2009
Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myelomaNicolaus Kröger, Anita Badbaran, Michael Lioznov, et al.
Hepatology (Baltimore, Md.)|April 9, 2014
Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolismNicola Oehler, Tassilo Volz, Oliver D Bhadra, et al.
Molecular Cancer Therapeutics|March 3, 2019
Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR AntibodiesJoseph Tintelnot, Natalie Baum, Christoph Schultheiß, et al.
Haematologica|August 11, 2022
Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapySusanna Carolina Berger, Boris Fehse, Nuray Akyüz, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 20, 2012
Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myelomaNicolaus Kröger, Anita Badbaran, Tatjana Zabelina, et al.
Journal of the American Society of Nephrology : JASN|February 4, 2017
IL-33-Mediated Expansion of Type 2 Innate Lymphoid Cells Protects from Progressive GlomerulosclerosisJan-Hendrik Riedel, Martina Becker, Kerstin Kopp, et al.
Blood|February 17, 2005
Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesisUte Modlich, Olga S Kustikova, Manfred Schmidt, et al.
Oncotarget|June 11, 2015
Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancerFriederike Braig, Manuela März, Aneta Schieferdecker, et al.
The Journal of Clinical Investigation|July 1, 2020
Glioma escape signature and clonal development under immune pressureCecile L Maire, Malte Mohme, Michael Bockmayr, et al.
Pageof 21